Nasdaq suspends Windtree (WINT): -80% in 24 hours, moving to OTC and BNB strategy in jeopardy

Related

Strategy Inc Capital Framework Puts $1.25B in Bitcoin Sales on the Table

Strategy Inc just rewired how it thinks about capital...

Uber Stock MACD Turns Bullish — But $78.20 Stands in the Way

Uber stock sits at a technical inflection point. Price...

Broadcom Stock Slides Below Key EMAs — But JPMorgan Sees $580

Broadcom stock is trapped between bearish technicals and a...

BE Stock Pops 6% on Russell 1000 News, but 18% Plunge Damage Lingers

BE stock is attempting to recover from last week’s...

Stablecoins and ETFs Risk: BIS Says $320B Market Isn’t Real Money

The Bank for International Settlements has a pointed message...

Share

The suspension from Nasdaq for Windtree Therapeutics (ticker WINT), due to non-compliance with listing requirements and accompanied by an intraday collapse of –80%, has sparked strong fears among investors and raised questions about the recent initiative of treasury in BNB (initial commitment of $60 million with potential up to $200 million), indicating an already fragile financial balance.

According to the collected data, the stock went from about $0.48 before the notice to $0.11 at the close on August 21, 2025, confirming the very substantial intraday loss. Industry analysts monitoring small-cap biotech companies note that similar situations typically lead to a compression of capitalization and a significant reduction in liquidity in the first weeks following the delisting.